Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2005 1
2006 2
2007 6
2008 3
2009 5
2010 2
2011 4
2012 6
2013 6
2014 5
2015 9
2016 11
2017 4
2018 6
2019 4
2020 4
2021 7
2022 2
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: mittra e. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: mittra e. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Del Rivero J, et al. Among authors: mittra es. J Clin Oncol. 2023 Nov 10;41(32):5049-5067. doi: 10.1200/JCO.23.01529. Epub 2023 Sep 29. J Clin Oncol. 2023. PMID: 37774329
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
McClellan K, Chen EY, Kardosh A, Lopez CD, Del Rivero J, Mallak N, Rocha FG, Koethe Y, Pommier R, Mittra E, Pegna GJ. McClellan K, et al. Among authors: mittra e. Cancers (Basel). 2022 Sep 29;14(19):4769. doi: 10.3390/cancers14194769. Cancers (Basel). 2022. PMID: 36230691 Free PMC article. Review.
Theranostics in Neuroendocrine Tumors.
Mallak N, O'Brien SR, Pryma DA, Mittra E. Mallak N, et al. Among authors: mittra e. Cancer J. 2024 May-Jun 01;30(3):185-193. doi: 10.1097/PPO.0000000000000723. Cancer J. 2024. PMID: 38753753 Review.
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE.
Mittra ES. Mittra ES. AJR Am J Roentgenol. 2018 Aug;211(2):278-285. doi: 10.2214/AJR.18.19953. Epub 2018 Jun 27. AJR Am J Roentgenol. 2018. PMID: 29949416 Review.
Clinically Approved Nanoparticle Imaging Agents.
Thakor AS, Jokerst JV, Ghanouni P, Campbell JL, Mittra E, Gambhir SS. Thakor AS, et al. Among authors: mittra e. J Nucl Med. 2016 Dec;57(12):1833-1837. doi: 10.2967/jnumed.116.181362. Epub 2016 Oct 13. J Nucl Med. 2016. PMID: 27738007 Free PMC article. Review.
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Eads JR, et al. Among authors: mittra e. Endocr Relat Cancer. 2023 Jul 11;30(8):e220206. doi: 10.1530/ERC-22-0206. Print 2023 Aug 1. Endocr Relat Cancer. 2023. PMID: 37184955 Free PMC article.
Response Assessment Criteria and Their Applications in Lymphoma: Part 1.
Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr R, Mittra E. Moghbel MC, et al. Among authors: mittra e. J Nucl Med. 2016 Jun;57(6):928-35. doi: 10.2967/jnumed.115.166280. Epub 2016 Apr 28. J Nucl Med. 2016. PMID: 27127227 Free article. Review.
88 results